All In Biotech

NDA 215029 · Medrx USA

Bondlido

Lidocaine · Topical · Amide Local Anesthetic; Antiarrhythmic

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 24, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

49,631

36,212 serious, 5,053 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

BONDLIDO (lidocaine topical system 10%) is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN). BONDLIDO contains lidocaine, an amide local anesthetic, and is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN) ( 1 ).

Mechanism: Lidocaine is an amide-type local anesthetic and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 24, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • BONDLIDO · LIDOCAINE 10% · SYSTEM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,671
  • pain3,213
  • fatigue3,108
  • nausea3,093
  • headache2,856
  • off label use2,678
  • dyspnoea2,217
  • pneumonia2,054
  • diarrhoea2,011
  • sinusitis1,951
  • vomiting1,886
  • fall1,739

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004281
2005257
2006318
2007314
2008376
2009451
2010531
20111,089
20121,215
2013757
20141,133
20151,871
20163,208
20172,539
20183,295
20194,120
20205,396
20213,785
20223,521
20233,880
20243,956
20254,122
20263,212

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Medrx USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.